Prospective validation of a urine-based proteomics test for predicting clinically significant prostate cancer in biopsy-naïve patients.

Precision Diagnostics in Prostate Cancer: Integrating Biomarkers, Imaging, Genomics, and Artificial Intelligence in Contemporary United States Practice

This review critically examines contemporary prostate cancer diagnostics within United States clinical practice, distinguishing established guideline-supported approaches from selectively used adjuncts and emerging technologies.

Recent advances in discriminating prostate cancer from benign prostatic diseases in the pre-biopsy population

Urinary Proteomics Enables Noninvasive and Longitudinal Monitoring of Tumor Burden Dynamics and Early Recurrence in Hepatocellular Carcinoma

This urine-based model enables dynamic assessment of tumor burden and early recurrence detection, surpassing conventional serum biomarkers and providing a clinically actionable tool for personalized surveillance and therapeutic decision-making in HCC.

Combined Urinary Prostate Cancer Risk Score Based on Levels of PCAT14, PCA3, SChLAP1, and TMPRSS2: ERG Biomarkers Detected Using Resistive Sensors

Prostate cancer is a common age-related malignancy among men, originating in the prostate epithelium, often asymptomatic in early stages. The first line of diagnosis, serum prostate-specific antigen evaluations, suffers from low specificity and sensitivity, leading to false positives and missed clinically significant c...

Emerging serum and urine biomarkers for non-invasive detection, risk stratification and prognostic assessment of prostate cancer: a systematic review

Serum and urine protein biomarkers may complement PSA-based testing to improve non-invasive PCa detection and risk stratification, thereby minimising PSA-associated overdiagnosis and avoiding unnecessary biopsies.

B-077 Multicenter Comparison of PSA Immunoassays: Analytical Bias and Its Impact on Prostate Cancer Screening

Prostate-specific antigen (PSA) testing plays a central role in prostate cancer screening and management, guiding clinical decisions from initial detection to biopsy and follow-up. However, total PSA (tPSA) results can vary across commercial immunoassays due to lack of testing harmonizations, potentially altering...